This page provides a timely snapshot of our most recent negotiation activity, including an overview of open files and updates on key milestones from the past 4 weeks.
How current is this information?
The content on this page is updated on an ongoing basis to reflect the most recent available information. Please note that updates about negotiation activity may take 1–2 weeks to be processed.
“Under consideration for negotiation” means we’re currently considering the evidence and gathering other information to inform the negotiation approach, including the drug’s eligibility for expedited negotiation pathways. Once negotiation activities are underway, the drug is in active negotiation.
Letters of engagement
We send letters of engagement (LOE) to manufacturers at the end of the consideration phase, to begin active negotiations. The drugs listed below have recently entered active negotiation.
| Brand name | Manufacturer | Indication | LOE date |
|---|---|---|---|
| Minjuvi | Incyte Biosciences Canada Corporation | in combination with rituximab and lenalidomide for the treatment of adult patients with grade 1, 2, or 3a relapsed or refractory follicular lymphoma. | 2026-07-27 |
| Tezspire | AstraZeneca Canada Inc. | As an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery | 2026-07-21 |
| Elrexfio | Pfizer Canada ULC | For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy. | 2026-07-31 |
| Jatenzo | Tolmar Pharmaceuticals Canada, Inc. | Testosterone replacement therapy | 2026-07-27 |
| Talvey (Active ENP) | Janssen Inc. | for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy | 2026-07-28 |
Letters of intent
A letter of intent (LOI) outlines the negotiated terms of an agreement between the pCPA and a manufacturer at the end of a successful negotiation. The list below reflects our latest LOIs.
| Title | Manufacturer | Indication | LOE date | LOI date |
|---|---|---|---|---|
| Talzenna | Pfizer Canada ULC | In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). | 2026-01-19 | 2026-07-27 |
| Anzupgo | LEO Pharma Inc. | Chronic hand eczema | 2026-02-25 | 2026-08-04 |
| Perjeta | Hoffmann-La Roche Ltd. | In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with early-stage HER2-positive breast cancer | 2026-02-11 | 2026-08-11 |
Negotiations ended without agreement
Both negotiating parties strive to reach timely agreements. In rare cases, alignment between manufacturers and the pCPA can’t be reached. Each negotiation is unique, and decisions are made based on the information available at the time.
The pCPA always welcomes unsolicited offers, should a manufacturer want to re-engage and go back to the negotiation table.
When agreements can’t be reached, public drug plans may make decisions about providing coverage through their exceptional access programs.
| Title | Manufacturer | Indication | LOE date | Close date |
|---|---|---|---|---|
| Erbitux | Eli Lilly Canada Inc. | Braftovi, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test | 2026-05-06 | 2026-07-31 |
| Braftovi | Pfizer Canada ULC | in combination with cetuximab and chemotherapy, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test. | 2026-03-25 | 2026-07-24 |
Negotiations that weren’t pursued - Last 4 weeks
We don’t pursue negotiations in cases where the drug’s health technology assessment (HTA) recommendations were negative or “do not reimburse.” Other reasons, such as the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected on the drug’s page in the database.
| Title | Manufacturer | Indication | Close date |
|---|---|---|---|
| Scemblix | Novartis Pharmaceuticals Canada Inc. | For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who have previously received 1 tyrosine kinase inhibitor (second line). | 2026-07-28 |